<sup>11</sup>C-PIB阳性的认知功能障碍患者临床、基因型及嗅觉特点

doi:10.3969/j.issn.1672-6731.2020.05.013

摘要/Abstract

摘要：

研究背景 总结¹¹C-匹兹堡复合物B（¹¹C-PIB）阳性的认知功能障碍患者临床、基因型和嗅觉功能特点。方法纳入2015年1月至2016年2月27例¹¹C-PIB阳性的认知功能障碍患者[包括19例阿尔茨海默病（AD）和8例轻度认知损害（MCI）]，采用简易智能状态检查量表（MMSE）、蒙特利尔认知评价量表（MoCA）和画钟测验（CDT）评价认知功能，神经精神科问卷（NPI）评价精神行为，日常生活活动能力量表（ADL）评价日常生活活动能力，汉密尔顿抑郁量表21项（HAMD-21）评价抑郁症状；聚合酶链反应-限制性片段长度多态性测定ApoE基因型；T&T嗅觉计定量检测嗅觉功能，测定察觉阈值和识别阈值。结果神经心理学测验比较，AD组MMSE总评分（P=0.000）及其时间定向力（P=0.031）、瞬时记忆（P=0.021）、延迟回忆（P=0.009）、计算力（P=0.000）、复述（P=0.038）、阅读（P=0.021）、书写（P=0.002）、视空间能力（P=0.039），以及MoCA评分（P=0.000）和CDT评分（P=0.020）均低于MCI组，ADL评分高于MCI组（P=0.000），而MMSE量表之地点定向力、命名、理解力，以及NPI和HAMD-21评分组间差异无统计学意义（均P>0.05）。两组嗅觉障碍发生率、察觉域值和识别阈值差异亦无统计学意义（均P>0.05）。不同ApoE基因型之间嗅觉障碍发生率差异有统计学意义（Fisher确切概率法：P=0.000），携带ApoEε4等位基因的患者嗅觉障碍发生率高于未携带该等位基因的患者（0/11对12/13；Fisher确切概率法：P=0.000）。结论 ¹¹C-PIB阳性的认知功能障碍患者（包括阿尔茨海默病和轻度认知损害）存在明显的嗅觉障碍，且与ApoEε4等位基因相关，结合不同临床、基因型和嗅觉功能特点有助于早期诊断阿尔茨海默病。

关键词: 认知障碍, 阿尔茨海默病, 正电子发射断层显像术, 载脂蛋白 E 类, 基因型, 嗅觉

Abstract:

Background To summarize the clinical, genotype and olfactory characteristic in patients with ¹¹C-Pittsburgh compound B (¹¹C-PIB)-positive cognitive impairment. Methods Twenty-seven patients with ¹¹C-PIB-positive cognitive impairment, including 19 patients with Alzheimer's disease (AD) and 8 patients with mild cognitive impairment (MCI), were recruited from January 2015 to February 2016 in Tianjin Huanhu Hospital. The clinical, genotype and olfactory profiles were retrospectively analyzed. Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) and Clock Drawing Test (CDT), Neuropsychiatric Inventory (NPI), Activity of Daily Living Scale (ADL), and Hamilton Depression Scale-21 (HAMD-21) were used to evaluate cognitive function, behavioral and psychological symptoms, activities of daily living, and symptoms of depression, respectively. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine ApoE genotype, and T& T olfactometer was used to test threshold of detection and recognition. Results Compared with MCI patients, AD patients had lower MMSE score (P=0.000), orientation to time (P=0.031), short-term memory (P=0.021), recall (P=0.009), calculation (P=0.000), repetition (P=0.038), reading (P=0.021), writing (P=0.002), visual-spatial ability (P=0.039), MoCA score (P=0.000) and CDT score (P=0.020), and higher ADL score (P=0.000). But there was no significant difference in orientation to place, naming, comprehension, NPI score and HAMD-21 score between 2 groups (P>0.05, for all). There were no statistical differences in incidence of olfactory dysfunction, threshold of detection and recognition between 2 groups (P>0.05, for all). There were statistical differences in the incidence of olfactory disorders among different ApoE genotypes (Fisher's exact probability:P=0.000). To further evaluate the effect of ApoEε4 allele on the olfactory function, subjects were additionally dichotomized according to the presence or absence of at least one ApoEε4 allele. Comparing with the subjects without ApoEε4 allele, the olfactory function decreased significantly in those with ApoEε4 allele (0/11 vs. 12/13; Fisher's exact probability:P=0.000). Conclusions The patients with ¹¹C-PIB-positive cognitive impairment (AD and MCI) had significant olfactory disturbance, which was related to ApoEε4 allele. The assessment of clinical, genotype and olfactory characteristic was helpful in early diagnosis of AD patients.

Key words: Cognition disorders, Alzheimer disease, Positron-emission tomography, Apolipoproteins E, Genotype, Smell

张惠红, 王盼, 豆玉超, 王艳, 张淼, 徐小林, 周玉颖. ¹¹C-PIB阳性的认知功能障碍患者临床、基因型及嗅觉特点[J]. 中国现代神经疾病杂志, 2020, 20(5): 448-454.

ZHANG Hui-hong, WAN Pan, DOU Yu-chao, WANG Yan, ZHANG Miao, XU Xiao-lin, ZHOU Yu-ying. Clinical, genotypic and olfactory characteristics of patients with ¹¹C-PIB-positive cognitive impairment[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(5): 448-454.

https://journal11.magtechjournal.com/cjcnn/CN/Y2020/V20/I5/448

参考文献

[1] Martin E, Boucher C, Fontaine B, Delarasse C. Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer's disease models:effects of aging and amyloid pathology[J]. Aging Cell, 2017, 16:27-38.
[2] Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, Baker SL, Rabinovici GD, Jagust WJ. Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging[J]. J Neurosci, 2018, 38:530-543.
[3] The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada[J]. Neurology, 2000, 55:66-73.
[4] He W, Liu D, Radua J, Li G, Han B, Sun Z. Meta-analytic comparison between PIB-PET and FDG-PET results in Alzheimer's disease and MCI[J]. Cell Biochem Biophys, 2015, 71:17-26.
[5] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7:263-269.
[6] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7:270-279.
[7] Tian JZ, Xie HG, Qin B, Fan DS, Shi J, Xiao WZ, Ni JN, Wei MQ, Lu T, Wang LN, Wang YH; The Research Group of Alzheimer's Disease Chinese. The diagnostic framework for screening Alzheimer's disease in the Chinese population[J]. Zhongghua Nei Ke Za Zhi, 2019, 58:91-101.[田金洲, 解恒革, 秦斌, 樊东升, 时晶, 肖卫忠, 倪敬年, 魏明清, 卢涛, 王鲁宁,王荫华; 中国老年保健协会阿尔茨海默病分会研究小组. 适用于中国人群的阿尔茨海默病筛查和诊断框架[J]. 中华内科杂志, 2019, 58:91-101.]
[8] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state":a practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res, 1975, 12:189-198.
[9] Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment:validity and utility in a memory clinic setting[J]. Can J Psychiatry, 2007, 52:329-332.
[10] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA:a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53:695-699.
[11] Wang T, Xiao S, Li X, Wang H, Liu Y, Su N, Fang Y. Reliability and validity of the Chinese version of the neuropsychiatric inventory in mainland China[J]. Int J Geriatr Psychiatry, 2012, 27:539-544.
[12] Eto F, Tanaka M, Chishima M, Igarashi M, Mizoguchi T, Wada H, Iijima S. Comprehensive activities of daily living (ADL) index for the elderly[J]. Nihon Ronen Igakkai Zasshi, 1992, 29:841-848.
[13] Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton Depression Rating Scale[J]. J Psychiatr Res, 2000, 34:3-10.
[14] Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI[J]. J Lipid Res, 1990, 31:545-548.
[15] Rombaux P, Collet S, Martinage S, Eloy P, Bertrand B, Negoias S, Hummel T. Olfactory testing in clinical practice[J]. B-ENT, 2009, 5 Suppl 13:39-51.
[16] Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, Tang Y, Qin Q, Wang F, Qiao Y, Shi S, Wang YJ, Du Y, Zhang J, Zhang J, Luo B, Qu Q, Zhou C, Gauthier S, Jia J; Group for the Project of Dementia Situation in China. Dementia in China:epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19:81-92.
[17] Bäckman K, Joas E, Waern M, Östling S, Guo X, Blennow K, Skoog I, Gustafson DR. 37 years of body mass index and dementia:effect modification by the ApoE genotype:observations from the prospective population study of women in Gothenburg, Sweden[J]. J Alzheimers Dis, 2015, 48:1119-1127.
[18] Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease[J]. Brain, 2007, 130:1777-1786.
[19] La Joie R, Perrotin A, de La Sayette V, Egret S, DoeuvreL C, Belliard S, Eustache F, Desgranges B, Chételat GL. Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia[J]. Neuroimage Clin, 2013, 3:155-162.
[20] Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer's disease[J]. Inter Psychogeriatrics, 2010, 22:346-372.
[21] Gillespie AK, Jones EA, Lin YH, Karlsson MP, Kay K, Yoon SY, Tong LM, Nova P, Carr JS, Frank LM, Huang Y. Apolipoprotein E4 causes age-dependent disruption of slow gamma oscillations during hippocampal sharp-wave ripples[J]. Neuron, 2016, 90:740-751.
[22] Scuteri A, Bos AJ, Zonderman AB, Brant LJ, Lakatta EG, Fleg JL. Is the ApoE4 allele an independent predictor of coronary events[J]? Am J Med, 2001, 110:28-32.
[23] Jung HJ, Shin IS, Lee JE. Olfactory function in mild cognitive impairment and Alzheimer's disease:a meta-analysis[J]. Laryngoscope, 2019, 129:362-369.
[24] Yaffe K, Freimer D, Chen H, Asao K, Rosso A, Rubin S, Tranah G, Cummings S, Simonsick E. Olfaction and risk of dementia in a biracial cohort of older adults[J]. Neurology, 2017, 88:456-462.
[25] Wilson RS, Arnold SE, Schneider JA, Tang Y, Bennett DA. The relationship between cerebral Alzheimer's disease pathology and odour identification in old age[J]. J Neurol Neurosurg Psychiatry, 2007, 78:30-35.
[26] Wilson RS, Schneider JA, Arnold SE, Tang Y, Bennett DA. Olfactory identification and incidence of mild cognitive impairment in older age[J]. Arch Gen Psychiatry, 2007, 64:802-808.
[27] Djordjevic J, Olfaction in patients with mild cognitive impairment and Alzheimer's disease[J]. Neurobiol Aging, 2008, 29:693-706.
[28] Li X, Jiao J, Shimizu S, Jibiki I, Watanabe K, Kubota T. Correlations between atrophy of the entorhinal cortex and cognitive function in patients with Alzheimer's disease and mild cognitive impairment[J]. Psychiatry Clin Neurosci, 2012, 66:587-593.
[29] Vasavada MM, Wang J, Eslinger PJ, Gill DJ, Sun X, Karunanayaka P, Yang QX. Olfactory cortex degeneration in Alzheimer's Alzheimers Dis, 2015, 45:947-958.
[30] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes[J]. Acta Neuropathol, 1991, 82:239-259.
[31] Devanand DP. Olfactory decline, and Psychiatry, 2016, 24:1151-1157.
[32] Christen-Zaech S, Kraftsik R, Pillevuit O, Kiraly M, Martins R, Khalili K, Miklossy J. Early olfactory involvement in Alzheimer's disease[J]. Can J Neurol Sci, 2003, 30:20-25.
[33] Attems J, Jellinger KA. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment[J]. Clin Neuropathol, 2006, 25:265-271.
[34] Oleson S, Murphy C. Olfactory dysfunction in ApoE ε 4/4 homozygotes with Alzheimer's disease[J]. J Alzheimer Dis, 2015, 46:791-803.
[35] Calhoun -Haney R, Murphy C. Apolipoprotein epsilon4 associated with more rapid decline in odor identification than in odor threshold or Dementia Rating Scale scores[J]. Brain Cogn, 2005, 58:178-182.
[36] Olofsson JK, Josefsson M, Ekstrom I, Wilson D, Nordin S, Nordin Adolfsson A, Adolfsson R, Nilsson LG, Larsson M. Long-term with olfactory deficits only in carriers of ApoE-Neuropsychologia, 2016, 85:1-9.
[37] Wolk DA, Dickerson BC; Alzheimer's Disease Neuroimaging Intervation. Apolipoprotein E (ApoE) genotype has dissociable effects on memory and attentional:executive network in Alzheimer's disease[J]. Proc Natl Acad Sci USA, 2010, 107:10256-10261.

选择文件类型/文献管理软件名称

选择包含的内容

2 ¹¹C-PIB阳性的认知功能障碍患者临床、基因型及嗅觉特点

Clinical, genotypic and olfactory characteristics of patients with ¹¹C-PIB-positive cognitive impairment

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	ApoE ε4与阿尔茨海默病专家共识编写组, 中国人体健康科技促进会神经变性病专业委员会, 国家神经系统疾病临床医学研究中心烟台区域分中心. ApoE ε4检测在阿尔茨海默病临床实践中的规范应用专家共识[J]. 中国现代神经疾病杂志, 2024, 24(8): 657-667.
[2]	王刚, 李彬寅, 任汝静, 肖金雯, 陈生弟, 陈晓春. 关于抗Aβ单克隆抗体的临床应用建议（2024版）[J]. 中国现代神经疾病杂志, 2024, 24(3): 120-126.
[3]	龚梦茜, 孙迎迎, 徐传英, 张伟, 祖洁, 崔桂云. 血清8-羟基脱氧鸟苷和丙二醛与帕金森病认知功能障碍的相关分析[J]. 中国现代神经疾病杂志, 2024, 24(3): 164-170.
[4]	姬莉, 杨宁, 刘卫国, 牛程麟. 老年帕金森病患者自主神经功能与认知功能的相关分析[J]. 中国现代神经疾病杂志, 2024, 24(3): 171-176.
[5]	李海江, 王朝东. 以痉挛性截瘫为首发症状的早发型家族性阿尔茨海默病3型一家系（附点评）[J]. 中国现代神经疾病杂志, 2023, 23(9): 853-858.
[6]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[7]	万亚会, 吕梦頔, 李征, 周凯丽, 高海静, 薛蓉. 慢性失眠合并阻塞性睡眠呼吸暂停患者睡眠结构和自主神经功能特征及其与神经心理特征相关分析[J]. 中国现代神经疾病杂志, 2023, 23(8): 693-708.
[8]	罗玲, 陈荣华, 肖迎春, 余尔涵, 潘晓东. 特发性快速眼动睡眠期行为障碍患者认知功能特点及其与睡眠结构相关性分析[J]. 中国现代神经疾病杂志, 2023, 23(6): 549-559.
[9]	刘庆, 孙萍. 主观认知下降临床研究进展[J]. 中国现代神经疾病杂志, 2023, 23(4): 275-281.
[10]	刘书雨, 张巍. 阿尔茨海默病相关心脏结构和功能损害[J]. 中国现代神经疾病杂志, 2023, 23(4): 282-286.
[11]	余彩遥, 叶兰, 冯占辉. 癫痫患者认知功能障碍相关危险因素研究进展[J]. 中国现代神经疾病杂志, 2023, 23(4): 287-291.
[12]	苏玉洁, 孙嫣, 凌怡, 张侃, 刘晓燕, 彭国平. 老年轻度认知损害患者抑郁情绪与认知功能相关性分析[J]. 中国现代神经疾病杂志, 2023, 23(4): 292-302.
[13]	孙艳, 范茹雪, 陈慧丰, 尹洁, 张楠. 天津市部分城市社区老年人群轻度认知损害患病情况及影响因素分析[J]. 中国现代神经疾病杂志, 2023, 23(4): 303-309.
[14]	乔雨晨, 常红, 王佳妹, 杨璇, 魏娜, 丁爱聪. 认知功能障碍患者激越行为特点及影响因素分析[J]. 中国现代神经疾病杂志, 2023, 23(4): 310-316.
[15]	姚莉萍, 王睿晗, 包翌, 蔡瀚林, 陈芹. 后部皮质萎缩临床及影像学特征分析[J]. 中国现代神经疾病杂志, 2023, 23(4): 326-334.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 11C-PIB阳性的认知功能障碍患者临床、基因型及嗅觉特点

Clinical, genotypic and olfactory characteristics of patients with 11C-PIB-positive cognitive impairment

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

2 ¹¹C-PIB阳性的认知功能障碍患者临床、基因型及嗅觉特点

Clinical, genotypic and olfactory characteristics of patients with ¹¹C-PIB-positive cognitive impairment